Contact
searchSearch
HMP Global
Login

News

News
Fewer Cycles of Platinum-Based Chemotherapy Potentially Preserves Outcomes and Tolerability in Advanced Urothelial Carcinoma
10/17/2025
Stephanie Holland
Results from the phase 3 DISCUS trial suggest that 3 cycles of platinum-based chemotherapy prior to avelumab maintenance may offer comparable efficacy and safety compared to the standard 6 cycle regimen for patients with advanced urothelial...
Results from the phase 3 DISCUS trial suggest that 3 cycles of platinum-based chemotherapy prior to avelumab maintenance may offer comparable efficacy and safety compared to the standard 6 cycle regimen for patients with advanced urothelial...
Results from the phase 3 DISCUS...
10/17/2025
Oncology
News
Fewer Cycles of Platinum-Based Chemotherapy Potentially Preserves Outcomes and Tolerability in Advanced Urothelial Carcinoma
10/17/2025
Stephanie Holland
Results from the phase 3 DISCUS trial suggest that 3 cycles of platinum-based chemotherapy prior to avelumab maintenance may offer comparable efficacy and safety compared to the standard 6 cycle regimen for patients with advanced urothelial...
Results from the phase 3 DISCUS trial suggest that 3 cycles of platinum-based chemotherapy prior to avelumab maintenance may offer comparable efficacy and safety compared to the standard 6 cycle regimen for patients with advanced urothelial...
Results from the phase 3 DISCUS...
10/17/2025
Oncology
Conference Coverage
Cemiplimab Added to Chemotherapy Shows Promise for Advanced Penile Carcinoma
02/13/2025
Allison Casey
According to a phase 2 study, cemiplimab plus standard-of-care chemotherapy demonstrated efficacy and safety among patients with locally advanced or metastatic penile carcinoma.
According to a phase 2 study, cemiplimab plus standard-of-care chemotherapy demonstrated efficacy and safety among patients with locally advanced or metastatic penile carcinoma.
According to a phase 2 study,...
02/13/2025
Oncology
News
Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer
01/14/2025
Stephanie Holland
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.
According to results from the...
01/14/2025
Oncology
Martijn Meijerink, MD, PhD, Amsterdam UMC
Videos
Thermal Ablation Non-Inferior to Surgery for Patients With Smaller Colorectal Liver Metastases
06/19/2024
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD, shares results from the COLLISION trial which compared thermal ablation to surgical resection for patients with smaller colorectal liver metastases.
Martijn Meijerink, MD, PhD,...
06/19/2024
Oncology
News
Multidisciplinary Tumor Boards Essential for Patients With Renal Cell Carcinoma
03/11/2024

Allison Casey

Allison Casey
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of multidisciplinary tumor board created the opportunity for shared decision making with patients when considering multiple treatment options and clinical trials.
A recent study found the use of...
03/11/2024
Oncology
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024
Stephanie Holland
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology
Conference Coverage
Nivolumab Plus Ipilimumab Improved Survival, Response Compared to Sunitinib Among Patients With Advanced Clear Cell Renal Cell Carcinoma
01/31/2024
Stephanie Holland
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from the phase 3 CheckMate-214 trial demonstrated that nivolumab plus ipilimumab improved survival and response compared to sunitinib among patients with advanced renal cell carcinoma.
Long-term follow-up data from...
01/31/2024
Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024
Stephanie Holland
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology
Conference Coverage
Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer
01/25/2024
Stephanie Holland
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...
Results from the ongoing phase 3...
01/25/2024
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use